Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Novo Nordisk's semaglutide delivers in phase 3 MASH study
With a positive readout for MASH now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.
Fraiser Kansteiner
Nov 1, 2024 10:38am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
Argenx sees early launch success for Vyvgart in CIDP
Nov 1, 2024 11:46am
FDA expert panel spurns Lexicon's approval bid in type 1 diabetes
Nov 1, 2024 11:24am
Novartis sings a new tune as official partner of Eurovision 2025
Nov 1, 2024 10:50am
Apotex, Heritage fork over $49M to resolve price-fixing claims
Nov 1, 2024 10:28am
Marketing News
Boehringer tops reputation rankings among CV patient groups
Oct 31, 2024 11:32am
Patient groups feel influence growing in healthcare: survey
Oct 31, 2024 2:00am
Biogen raises profit guidance as Leqembi's launch trudges on
Oct 30, 2024 12:30pm
Almirall focuses on role of friends and family for psoriasis day
Oct 30, 2024 11:51am
See More Marketing News